Replies to post #119764 on Biotech Values

[biomaven0]

I didn't see much in the way of more recent releases from Ambit (that looks like it was from 2008) - maybe because they are now partnered with Astellas and I happen to know that Astellas likes to keep things quiet.

Here are the current clinical trials for AC220:

http://clinicaltrials.gov/ct2/results?term=ac220

[biomaven0]

Let me make one more comment on FLT3 in AML.

While it may be the case that pona works magic in this indication too, it is much more likely that this is an indication much different from CML or the ALK space. In other words, the drug will likely not be a magic bullet where you can tell in a Phase I whether you have an approvable drug or not. Instead you have to do the hard work of multiple trials, refining the dose, finding biomarkers and good drug combinations and so on. In other words, big pharma territory.

Peter